Loading...

Home
Stock
VNRX

VNRX Overview

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

Loading chart...

High

0.182

Open

0.179

VWAP

0.18

Vol

4.78M

Mkt Cap

28.34M

Low

0.172

Amount

850.86K

EV/EBITDA(TTM)

--

Total Shares

158.48M

EV

36.99M

EV/OCF(TTM)

--

P/S(TTM)

10.92

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

Show More

Events Timeline

(ET)

2026-03-06

08:20:00

VolitionRx Completes Validation of Nu.Q Vet Cancer Test

2026-02-09 (ET)

2026-02-09

17:30:00

VolitionRx Receives NYSE Warning, Must Submit Compliance Plan

2026-02-09

17:20:00

VolitionRx Files to Sell 17.97M Shares of Common Stock

2026-01-20 (ET)

2026-01-20

08:30:00

VolitionRx Appoints New Lab Providers to Expand Nu.Q Vet Cancer Test

2026-01-08 (ET)

2026-01-08

08:50:00

VolitionRx Announces Results of Cat Lymphoma Detection Study

2025-12-11 (ET)

2025-12-11

09:20:00

VolitionRx Releases Manuscript Showcasing New Cancer Biomarkers for Liquid Biopsy

News

Yahoo Finance

04-03Yahoo Finance

VolitionRX Reports 133% Revenue Growth in Q4 2025

Significant Revenue Growth: VolitionRX achieved a remarkable 133% year-on-year growth in Q4 2025, with total revenue reaching $1.7 million for the year, a 40% increase over 2024, indicating strong demand and potential market expansion in cancer detection.
Operating Expenses Reduced: The company successfully cut operating expenses by $4.8 million, a 17% decrease compared to 2024, demonstrating effective cost control measures that enhance overall financial health.
Cash Flow Warning: Despite revenue growth, net cash used in operating activities was $19.7 million in 2025, down from $25.9 million in 2024; however, cash and cash equivalents were only approximately $1.1 million, highlighting the urgent need for additional funding to sustain operations.
Strategic Partnership Progress: VolitionRX signed significant agreements with Werfen and Hologic to commercialize its Nu.Q platform, marking a crucial step in the company's strategic positioning within the clinical diagnostics market, which is expected to drive future revenue growth.

seekingalpha

04-01seekingalpha

VolitionRx Q4 2025 Earnings Call Highlights

New Product Orders: In Q4 2025, VolitionRx secured its first order for Nu.Q Cancer assays for clinical certification, marking a significant advancement towards routine clinical use in lung cancer, which is expected to drive future market demand and revenue growth.
Significant Revenue Growth: The company reported full-year revenue of $1.7 million for 2025, reflecting a 40% increase, while operating expenses decreased by 17%, indicating substantial progress in cost control that will enhance profitability.
Strategic Partnership Agreements: VolitionRx initiated its human licensing strategy by signing two agreements with Hologic and Werfen, which will help expand market reach and strengthen collaborations with industry leaders.
Future Outlook: Although management did not provide revenue guidance for 2026, they anticipate continuing to pursue multiple licensing agreements and aim to further reduce cash operating expenses by 25%-30%, enhancing financial flexibility and market competitiveness.

seekingalpha

04-01seekingalpha

VolitionRX Reports 40% Revenue Growth in FY

Fiscal Year Revenue Growth: VolitionRX reported FY revenue of $1.7 million, representing a 40% increase over the previous year, indicating the company's sustained growth potential in the competitive biotechnology sector.
Reduced Net Loss: The company's net loss decreased by 14% compared to 2024, suggesting effective cost control measures that improve financial health and bolster investor confidence.
Improved Cash Utilization: Cash used in operating activities was $19.7 million, down 24% year-over-year, reflecting optimization in resource allocation and operational efficiency, potentially providing more flexibility for future investments.
Non-Dilutive Funding Secured: VolitionRX secured €2 million in non-dilutive funding from Belgian agencies, which will support its R&D and market expansion efforts, further solidifying its position in the industry.

seekingalpha

03-31seekingalpha

VolitionRx Secures €2 Million Non-Dilutive Financing

Funding for Development: VolitionRx secured €2 million in non-dilutive financing from Namur Invest and Wallonie Entreprendre, which will be used to support the development of its Nu.Q product portfolio, particularly the regulatory transition work for Nu.Q NETs, potentially accelerating the product's market entry.
Strategic Financing Plan: This financing is part of the company's strategy to secure non-dilutive funding for ongoing development, with total non-dilutive funding to date exceeding $25 million, enhancing the company's financial stability and R&D capabilities.
Improving Access in Low-Income Countries: The funds will be directed towards the development of a lateral flow product aimed at improving access to medical products in low-income countries, reflecting the company's commitment to global health equity while laying the groundwork for future market expansion.
Stock Price Reaction: Following the financing announcement, VolitionRx's stock price rose by 0.05% in pre-market trading to $0.1901, indicating a positive market sentiment regarding the company's financing and growth prospects.

Newsfilter

03-30Newsfilter

Nu.Q® Biomarkers Clinical Study Published in Shock Journal

Clinical Study Findings: VolitionRx's research reveals that nucleosome levels, specifically Nu.Q® H3.1 and H3R8 Citrulline, are significantly elevated in 674 trauma patients post-injury, particularly in those who develop Venous Thromboembolism (VTE), indicating the potential clinical utility of these biomarkers in trauma care.
Importance of Biomarkers: The study underscores the clinical challenge of identifying reliable biomarkers in trauma patients, especially in emergency and surgical settings, suggesting that these findings could support early risk identification and targeted preventive strategies, ultimately improving patient outcomes.
Commercialization Prospects: The peer-reviewed publication with the Mayo Clinic research team strongly supports Volition's efforts to commercialize its Nu.Q® NETs product, indicating promising market opportunities in the trauma care sector.
Future Research Directions: Researchers indicate that Nu.Q® NETs may assist clinicians and researchers in anticipating disease, guiding treatment decisions, and monitoring patients, showcasing broad application potential across acute and chronic conditions.

Newsfilter

03-25Newsfilter

VolitionRx to Host Earnings Call on April 1, 2026

Earnings Call Announcement: VolitionRx will host a conference call on April 1, 2026, at 8:30 a.m. U.S. Eastern Time to discuss its financial and operational results for fiscal year 2025, aiming to provide investors with the latest business updates.
Key Participants: The call will be hosted by Group Chief Marketing & Communications Officer Louise Batchelor, with participation from President and CEO Cameron Reynolds, CFO Terig Hughes, and other executives, ensuring a comprehensive interpretation of significant company events and future milestones.
Replay Information: A telephone replay of the call will be available until April 15, 2026, with a toll-free dial-in number of 1-844-512-2921 for the U.S. and Canada, and an international number of 1-412-317-6671, ensuring that investors who cannot attend live can access key information.
Company Overview: VolitionRx focuses on advancing the science of epigenetics, dedicated to improving the quality of life for humans and animals through early detection and monitoring of diseases, developing simple and cost-effective blood tests to detect cancers and diseases associated with NETosis, highlighting its strategic importance in the healthcare sector.

Wall Street analysts forecast VNRX stock price to rise

3 Analyst Rating

Wall Street analysts forecast VNRX stock price to rise

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

1.50

Averages

2.25

High

3.00

Current: 0.000

Low

1.50

Averages

2.25

High

3.00

H.C. Wainwright

H.C. Wainwright

Buy

downgrade

$1

AI Analysis

2026-04-02

Reason

H.C. Wainwright

H.C. Wainwright

Price Target

$1

AI Analysis

2026-04-02

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on VolitionRx to $1 from $1.50 and keeps a Buy rating on the shares after the company reported Q4 results. The firm, which believes that the company could secure additional human licensing deals in 2026 to help drive topline revenue growth, cites an increased share count for its lowered target.

Maxim

Buy

to

Hold

downgrade

2025-12-03

Reason

Maxim

Price Target

2025-12-03

downgrade

Buy

to

Hold

Reason

Maxim downgraded VolitionRx to Hold from Buy.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VNRX

Unlock Now

Valuation Metrics

The current forward P/E ratio for VolitionRX Ltd (VNRX.A) is 10.53, compared to its 5-year average forward P/E of -3.03. For a more detailed relative valuation and DCF analysis to assess VolitionRX Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-3.03

Current PE

10.53

Overvalued PE

1.05

Undervalued PE

-7.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.46

Current EV/EBITDA

-0.07

Overvalued EV/EBITDA

0.36

Undervalued EV/EBITDA

-3.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

61.40

Current PS

0.57

Overvalued PS

152.64

Undervalued PS

-29.83

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

all penny stocks out there

Intellectia · 1059 candidates

Region: USPrice: $0.00 - $5.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

iSpecimen Inc

3.23M

Maison Solutions Inc

4.26M

Virax Biolabs Group Ltd

1.10M

Cheetah Net Supply Chain Service Inc (Pre-Reincorporation)

60.78M

VolitionRX Ltd

25.37M

Lixiang Education Holding Co Ltd

3.45M

Intellectia · 4 candidates

Market Cap: 20.00M - 500.00MRegion: USPrice: $0.01 - $0.25List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

NUBURU Inc

29.84M

VolitionRX Ltd

26.28M

KALA BIO Inc

185.00M

Outlook Therapeutics Inc

26.05M

sort list ny market cap

Intellectia · 32 candidates

Price: $0.00 - $0.25Volume: >= 500,000Market Cap Category: micro, nano

Ticker

Name

Market Cap$

KALA BIO Inc

185.00M

Nakamoto Inc

150.98M

Hyperscale Data Inc

62.91M

Srx Health Solutions Inc

45.86M

Atlasclear Holdings Inc

35.12M

NUBURU Inc

29.84M

top penny stocks under $0.25

Intellectia · 32 candidates

Price: $0.00 - $0.25Volume: >= 500,000Market Cap Category: micro, nano

Ticker

Name

Market Cap$

iSpecimen Inc

3.80M

Wellgistics Health Inc

12.58M

zSpace, Inc.

2.85M

Virax Biolabs Group Ltd

1000.00K

Hyperscale Data Inc

62.91M

CXApp Inc

10.40M

What are the top penny stocks under $0.25

Intellectia · 26 candidates

Price: $0.00 - $0.25Volume: >= 500,000Market Cap Category: micro, nanoList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Quince Therapeutics Inc

10.20M

Hyperscale Data Inc

54.64M

Inno Holdings Inc

8.75M

Virax Biolabs Group Ltd

1.11M

Hub Cyber Security Ltd

431.94K

NUBURU Inc

29.16M

penny stocks under $1.00

Intellectia · 330 candidates

Price: $0.00 - $1.00Market Cap Category: micro, nanoList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Jet.AI Inc

9.67M

zSpace, Inc.

3.46M

Quince Therapeutics Inc

4.87M

Cenntro Inc (The Corporation)

10.22M

Hub Cyber Security Ltd

161.60K

Scworx Corp

1.98M

penny stocks positive most active today

Intellectia · 75 candidates

Price: $0.10 - $5.00Volume: >= 1,000,000Price Change Pct: >= $0.10

Ticker

Name

Market Cap$

ICZOOM Group Inc

10.57M

Peloton Interactive Inc

1.88B

Denison Mines Corp

3.08B

Kosmos Energy Ltd

1.73B

Baytex Energy Corp

3.20B

Globavend Holdings Ltd

3.20M

Help me find stocks that are under 2.00

Intellectia · 531 candidates

Region: USPrice: <= $2.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Applied Therapeutics Inc

14.24M

China SXT Pharmaceuticals Inc

11.42M

Jin Medical International Ltd

25.25M

Cenntro Inc (The Corporation)

13.35M

NUBURU Inc

76.36M

urban-gro Inc

3.10M

biotech industry stock under 5 dollars

Intellectia · 282 candidates

Industry: Biotechnology & Medical ResearchPrice: <= $5.00

Ticker

Name

Market Cap$

Applied Therapeutics Inc

14.63M

Theriva Biologics Inc

6.85M

IO Biotech Inc

14.94M

Adial Pharmaceuticals Inc

6.04M

GRI Bio Inc

2.26M

Propanc Biopharma Inc

3.62M

stovks to buy on wed from 20 to 40 cents

Intellectia · 81 candidates

Price: $0.20 - $0.40

Ticker

Name

Market Cap$

Sangamo Therapeutics Inc

127.97M

Incannex Healthcare Inc

123.43M

Hyperscale Data Inc

96.48M

Aurelion Inc

95.26M

Robo.ai Inc

89.22M

CleanCore Solutions Inc

79.36M

Whales Holding VNRX

Trading Trends

Insider

Hedge Fund

Congress Trading

People Also Watch

Frequently Asked Questions

What is VolitionRX Ltd (VNRX) stock price today?

The current price of VNRX is 0.1788 USD — it has increased 1.7

What is VolitionRX Ltd (VNRX)'s business?

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

What is the price predicton of VNRX Stock?

Wall Street analysts forecast VNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNRX is2.25 USD with a low forecast of 1.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is VolitionRX Ltd (VNRX)'s revenue for the last quarter?

VolitionRX Ltd revenue for the last quarter amounts to 447.03K USD, increased 133.25

What is VolitionRX Ltd (VNRX)'s earnings per share (EPS) for the last quarter?

VolitionRX Ltd. EPS for the last quarter amounts to -0.05 USD, decreased -16.67

How many employees does VolitionRX Ltd (VNRX). have?

VolitionRX Ltd (VNRX) has 75 emplpoyees as of April 19 2026.

What is VolitionRX Ltd (VNRX) market cap?

Today VNRX has the market capitalization of 28.34M USD.